The Economic Times, November 12 report: According to the India-China Economic and Cultural Commission (ICEC), several Indian pharmaceutical companies have successfully won bids in the centralized procurement bidding (VBP) organized by China's National Health Commission. This round of bidding covers 55 drugs, including anti-infective, anti-cancer, and anti-allergy categories, with a total of 272 companies and 453 products entering the pre-bid. Among them, Indian companies have obtained contracts for seven drugs: Hetero Drugs Ltd and Cipla Ltd jointly supply ten billion tablets of Dapagliflozin for the treatment of diabetes; Annora Pharma Pvt Ltd won the bid for Oxcarbazepine Tablets; Natco Pharma won the bid for Olaparib Tablets. In addition, the Chinese subsidiary of Dr. Reddy's Laboratories, Kunshan Rotam Reddy Pharmaceutical Co, also won the bid for four drugs. Analysts pointed out that the milestone significance of Indian pharmaceutical companies winning the VBP in China. On one hand, Indian pharmaceutical companies focus on the generic drug market in China, and the VBP is their only way to enter the Chinese drug market. Currently, only about 10 Indian pharmaceutical companies are operating in China, some of which have already built local production capacity. On the other hand, India has long been calling for China to open up its domestic drug and IT markets to alleviate the huge trade deficit with China. Overall, Indian pharmaceutical companies still face many challenges in developing in China, including limited comprehensive competitiveness and high dependence on Chinese raw materials. Therefore, if Indian pharmaceutical companies want to stand out in the Chinese market, they must accelerate the development and registration process of their products in China and expand their production scale to achieve "cost leadership".
Original: www.toutiao.com/article/1848693800374339/
Statement: The article represents the views of the author.